FDA Accepts Supplement Application for RYTELLO (Imetelstat Sodium)
The FDA has accepted the supplemental application for RYTELLO, an imetelstat sodium product.
Asset / Drug
Drug and asset intelligence for Geron with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Telomerase Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.